# Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease

> **NCT06541691** · NA · RECRUITING · sponsor: **Rajaie Cardiovascular Medical and Research Center** · enrollment: 3000 (estimated)

## Conditions studied

- Atherosclerotic Cardiovascular Disease
- Coronary Artery Disease
- Ischemic Heart Disease
- Ischemic Stroke
- Peripheral Arterial Disease
- Carotid Artery Stenosis
- Carotid Atherosclerosis

## Interventions

- **DRUG:** Enteric-coated aspirin
- **DRUG:** Plain aspirin
- **OTHER:** Hybrid strategy

## Key facts

- **NCT ID:** NCT06541691
- **Lead sponsor:** Rajaie Cardiovascular Medical and Research Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-06
- **Primary completion:** 2026-03-30
- **Final completion:** 2027-03-30
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2025-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06541691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06541691, "Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06541691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*